Reference Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type
PMID
Authors ST. Durant, KG. Pike, N Colclough, L Riches, A Garcia-Trinidad, T Hunt, S Ling, J Stott, I Barrett, L Zheng, Y Wang, K Chen, T Zhang, VP Reddy, A Sykes, P Johnstrom, G Jones, A Pierce, J Karlin, J Kahn, J Allen, K Valerie, R Illingworth and M Pass
Title AZD1390, a potent and selective orally bioavailable blood-brain barrier-penetrant ATM inhibitor, radiosensitizes and improves survival of orthotopic glioma and metastatic brain tumor models
Journal Vol Issue Date Pages Journal Short Title
Mol Cancer Ther
URL http://mct.aacrjournals.org/content/17/1_Supplement/A104
Abstract Text Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
AZD1390 AZD1390 3 7
Drug Name Trade Name Synonyms Drug Classes Drug Description
AZD1390 AZD 1390|AZD-1390 ATM Inhibitor 13 AZD1390 is a selective inhibitor of ATM that is optimized for blood-brain barrier penetration, thus may preferentially sensitize CNS tumors for radiotherapy (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104, PMID: 29938225, PMID: 31299316).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ATM positive lung cancer sensitive AZD1390 Preclinical - Cell line xenograft Actionable In a preclinical study, AZD1390 inhibited Atm activity, sensitized lung cancer cells to radiotherapy in culture, and demonstrated efficacy in cell line xenograft models (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104). detail...
TP53 mutant glioblastoma sensitive AZD1390 Preclinical - Cell culture Actionable In a preclinical study, TP53 mutant glioblastoma cells demonstrated increased sensitivity to radiosensitization by AZD1390 treatment compared to TP53 wild-type cells in culture (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104). detail...
ATM positive glioblastoma sensitive AZD1390 Preclinical - Cell line xenograft Actionable In a preclinical study, AZD1390 inhibited Atm activity, sensitized glioblastoma cell lines to radiotherapy in culture, and demonstrated efficacy in mouse models of glioblastoma (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104). detail...